XCF Global Inc Reports Strong FY Earnings Amid Market Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy SAFX?
Source: seekingalpha
XCF Global Inc's stock surged by 52.40% as it crossed above the 5-day SMA, reflecting strong investor interest.
The company reported a FY GAAP EPS of $0.52 and revenue of $20.82 million, indicating stable profitability and growth compared to the previous year. This performance reassures investors about the company's financial health and competitive position in the market.
The positive earnings report enhances confidence in XCF Global's future growth, especially in the context of a rising market, as both the Nasdaq-100 and S&P 500 indices show significant gains.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SAFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SAFX
About SAFX
XCF Global, Inc. is a sustainable aviation fuel company engaged in accelerating the aviation industry's transition to net-zero emissions. The Company is developing and operating clean fuel synthetic aviation fuel (SAF) production facilities. SAF is a synthetic kerosene derived from non-food feedstocks, such as waste oils and fats, green and municipal waste and non-food crops. SAF is able to recycle carbon dioxide absorbed by biomass during its lifetime rather than injecting new carbon into the system, reducing emissions by up to 80%. It is also engaged in building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XCF Global Assesses Notice and Financial Implications, Engages in Talks with Phillips 66 - SEC Filing
- Financial Evaluation: Discussions are ongoing regarding the financial impact of evaluating notices.
- Involvement of Phillips: The evaluation process includes consultations with Phillips, indicating a collaborative approach.
See More
XCF Global Inc: Phillips 66 to End Supply and Offtake Agreement with New Rise Renewables Reno Starting May 1, 2026 - SEC Filing
Supply Termination: Global Inc. has announced the termination of its supply agreement with New Riser Renewables, effective May 1, 2026.
Offtake Agreement: The termination also includes an offtake agreement, indicating a significant shift in their business relationship.
See More
XCF GLOBAL INC - SEC FILING REVEALS INITIAL THREE-YEAR TERM FROM PRODUCTION START IN TERM SHEET
- Global Interterm Sheet: The Global Interterm Sheet has initiated a three-year term from the start of production.
- SEC Filing: The relevant details have been filed with the SEC.
See More
XCF GLOBAL INC - SIGNS TERM SHEET FOR RENEWABLE FUEL TOLLING AGREEMENT WITH BGN DATED APRIL 9, 2026 - SEC FILING
Global Renewable Fuel Tolling Agreement: Global Inc. has entered into a renewable fuel tolling agreement with BGN, effective April 9, 2026.
SEC Filing: The details of this agreement have been filed with the SEC, indicating compliance with regulatory requirements.
See More
XCF Global, Inc. Reports FY Earnings
- Earnings Highlights: XCF Global, Inc. reported a FY GAAP EPS of $0.52, indicating stable profitability amidst market challenges, which may reassure investors about the company's financial health.
- Revenue Performance: The company achieved revenue of $20.82 million, showing growth compared to the previous year, reflecting its competitive position in the market and sustained customer demand, which enhances confidence in future growth.
- Quant Rating Insight: Seeking Alpha's Quant Rating on XCF Global, Inc. provides an in-depth analysis of the company's financial health, aiding investors in understanding its market positioning and potential investment value.
- Historical Data Context: The historical earnings data for XCF Global, Inc. offers crucial context for analyzing its long-term performance, allowing investors to assess growth trends and future prospects.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
XCF Global Assesses Notice and Financial Implications, Engages in Talks with Phillips 66 - SEC Filing
- Financial Evaluation: Discussions are ongoing regarding the financial impact of evaluating notices.
- Involvement of Phillips: The evaluation process includes consultations with Phillips, indicating a collaborative approach.
See More
XCF Global Inc: Phillips 66 to End Supply and Offtake Agreement with New Rise Renewables Reno Starting May 1, 2026 - SEC Filing
Supply Termination: Global Inc. has announced the termination of its supply agreement with New Riser Renewables, effective May 1, 2026.
Offtake Agreement: The termination also includes an offtake agreement, indicating a significant shift in their business relationship.
See More
XCF GLOBAL INC - SEC FILING REVEALS INITIAL THREE-YEAR TERM FROM PRODUCTION START IN TERM SHEET
- Global Interterm Sheet: The Global Interterm Sheet has initiated a three-year term from the start of production.
- SEC Filing: The relevant details have been filed with the SEC.
See More
XCF GLOBAL INC - SIGNS TERM SHEET FOR RENEWABLE FUEL TOLLING AGREEMENT WITH BGN DATED APRIL 9, 2026 - SEC FILING
Global Renewable Fuel Tolling Agreement: Global Inc. has entered into a renewable fuel tolling agreement with BGN, effective April 9, 2026.
SEC Filing: The details of this agreement have been filed with the SEC, indicating compliance with regulatory requirements.
See More
XCF Global, Inc. Reports FY Earnings
- Earnings Highlights: XCF Global, Inc. reported a FY GAAP EPS of $0.52, indicating stable profitability amidst market challenges, which may reassure investors about the company's financial health.
- Revenue Performance: The company achieved revenue of $20.82 million, showing growth compared to the previous year, reflecting its competitive position in the market and sustained customer demand, which enhances confidence in future growth.
- Quant Rating Insight: Seeking Alpha's Quant Rating on XCF Global, Inc. provides an in-depth analysis of the company's financial health, aiding investors in understanding its market positioning and potential investment value.
- Historical Data Context: The historical earnings data for XCF Global, Inc. offers crucial context for analyzing its long-term performance, allowing investors to assess growth trends and future prospects.
See More
The Oncology Institute Reports Strong Q4 Results, Shares Surge
- Earnings Beat: The Oncology Institute reported a Q4 loss of 6 cents per share, outperforming the analyst consensus estimate of a 9-cent loss, indicating improvements in cost management and operational efficiency, which boosts market confidence in its future profitability.
- Sales Growth: The company achieved quarterly sales of $141.957 million, exceeding the analyst consensus of $139.775 million, reflecting positive progress in market demand and product promotion, thereby strengthening its market position in oncology treatment.
- Stock Surge: Shares of The Oncology Institute jumped 14.7% to $3.01 in pre-market trading, demonstrating a positive investor reaction to the financial results, which may attract more investor interest in its future developments.
- Increased Market Confidence: The better-than-expected performance not only enhances investor confidence but may also prompt analysts to reassess the company's long-term growth potential, potentially influencing future stock price movements and market performance.
See More
